Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Net Margin (2021 - 2025)

SAB Biotherapeutics' Net Margin history spans 5 years, with the latest figure at 23845.69% for Q4 2025.

  • For Q4 2025, Net Margin rose 3378022.0% year-over-year to 23845.69%; the TTM value through Dec 2025 reached 17664.06%, up 2024308.0%, while the annual FY2024 figure was 2579.03%, 69453.0% down from the prior year.
  • Net Margin reached 23845.69% in Q4 2025 per SABSW's latest filing, down from 27873.57% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 27873.57% in Q3 2025 to a low of 9934.52% in Q4 2024.
  • Average Net Margin over 5 years is 2298.84%, with a median of 104.46% recorded in 2021.
  • Peak YoY movement for Net Margin: tumbled -797092bps in 2023, then surged 3378022bps in 2025.
  • A 5-year view of Net Margin shows it stood at 104.46% in 2021, then plummeted by -249bps to 364.42% in 2022, then plummeted by -1956bps to 7493.75% in 2023, then tumbled by -33bps to 9934.52% in 2024, then surged by 340bps to 23845.69% in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Net Margin are 23845.69% (Q4 2025), 27873.57% (Q3 2025), and 15718.81% (Q2 2025).